Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 154

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 15
Chunk 154
---
ICIT) $58,459  $687,486 

The accompanying notes are an integral part of these financial statements.

 F-4Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Operations

  Year Ended   December 31,   2023  2022        Revenues $-  $658,500 Cost of revenues  -   518,000 Gross profit  -   140,500          Operating expenses        Selling, general and administrative   3,517,542   5,930,237 Research and development  4,794,825   10,080,000 Provision for doubtful accounts  480,000   - Provision for purchase deposit write-off  12,000   -    Total operating expenses  8,804,367   16,010,237          Loss from operations  (8,804,367)  (15,869,737)         Other expense        Interest expense - related parties  3,206   1,706    Total other expenses  3,206   1,706          Loss before income tax expense  (8,807,573)  (15,871,443)Income tax expense   -   - Net loss $(8,807,573) $(15,871,443)         Basic and diluted loss per share of common stock $(0.15) $(0.26)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these financial statements.

 F-5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

  Preferred Stock  Common Stock  Additional Paid in   Deferred stock  Accumulated  Total Stockholders' Equity     Shares    Amount    Shares    Amount    Capital   compensation   Deficit  (Deficit)                          Balance, December 31, 2021  -  $-   60,042,000  $60,042  $32,293,530